Small-Cap Stock Spotlight: Threshold Pharmaceuticals Inc. (THLD) Spikes on Multi-Million Cancer Drug Pact with Merck KGaA
  • Small-Cap Stock Spotlight: Threshold Pharmaceuticals Inc. (THLD) Sets a New 52-Week High
  • Positive study data widens market reach for Amarin’s triglyceride drug
  • " />

    Threshold Pharmaceuticals (THLD) Surges on Positive Pancreatic Cancer Drug Study

    Threshold Pharmaceuticals (THLD) Surges on Positive Pancreatic Cancer Drug Study

    Shares in Threshold Pharmaceuticals (THLD) traded higher on Tuesday after the biotechnology company reported positive results from a study on its drug for advanced pancreatic cancer, TH-302. The stock set a new 52-week high of $6.65 before closing at $5.01, up 41.9% for the day.  Over 28 million shares traded hands during the session, topping the 10-day average of 2.23 million.

    Threshold reported that its 214 patient randomized controlled Phase 2b clinical trial evaluating the efficacy and safety of two doses of the investigational agent TH-302 in combination with gemcitabine compared to gemcitabine alone in patients with first-line advanced pancreatic cancer achieved its primary endpoint, with a 63% improvement in progression free survival and a safety profile consistent with previous studies.

    Threshold stated that the combination was well tolerated with a safety profile that was consistent with its prior study of the combination regimen.

    “This study provides the proof of concept demonstration that TH-302 contributes to the efficacy of a known active agent and supports the rationale for combining TH-302, a hypoxia targeting agent, with other approved therapies,” commented Stew Kroll, senior VP of biostatistics and clinical oerations of Threshold.

    The primary endpoint of the trial is progression-free survival. The secondary endpoints are overall response rate, overall survival, change in CA19-9 as well as various other efficacy and safety parameters.

    “With the results of this trial, we are again very encouraged that TH-302 is conferring benefit to patients with aggressive and difficult-to-treat cancers,” Threshold CEO Barry Selick said in a press release.

    Threshold looks forward to its ongoing development with its partner, German drug maker Merck KGaA, in this and other indications, Selick stated. Threshold announced its partnership agreement with Merck KGaA earlier this month.

    South San Francisco, CA-based Threshold focuses on the discovery and development of drugs targeting tumor hypoxia, the low oxygen condition found in microenvironments of most solid tumors as well as the bone marrows of some hematologic malignancies. TH-302 is a hypoxia-targeted drug that is thought to be activated under tumor hypoxic conditions, a hallmark of many cancer indications.

    Shares in Threshold have spiked 67.0% in the last five days; 227.5% in the last month; and 114.1% year-to-date.

    Leave a Reply

    Your email address will not be published. Required fields are marked *